dc.relation.reference | 1. Nishiyama, Y., Herpes simplex virus gene products: the accessories reflect her lifestyle well. Rev Med Virol, 2004. 14(1): p. 33-46.
2. Honess, R.W. and B. Roizman, Regulation of herpesvirus macromolecular synthesis. I. Cascade regulation of the synthesis of three groups of viral proteins. J Virol, 1974. 14(1): p. 8-19.
3. DM Knipe, P.H.E., Fields Virology, ed. t. Edn). 2001: Lippincott Williams & Wilkins.
4. Beck, T.W. and R.L. Millette, Regulation of herpes simplex virus gene transcription in vitro. J Cell Biochem, 1982. 19(4): p. 333-47.
5. Mackem, S. and B. Roizman, Structural features of the herpes simplex virus alpha gene 4, 0, and 27 promoter-regulatory sequences which confer alpha regulation on chimeric thymidine kinase genes. J Virol, 1982. 44(3): p. 939-49.
6. Kleymann, G., Novel agents and strategies to treat herpes simplex virus infections. Expert Opin Investig Drugs, 2003. 12(2): p. 165-83.
7. Sullivan, K.M., et al., Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Hematology (Am Soc Hematol Educ Program), 2001: p. 392-421.
8. Liesegang, T.J., Herpes simplex virus epidemiology and ocular importance. Cornea, 2001. 20(1): p. 1-13.
9. Kimberlin, D.W., Neonatal herpes simplex infection. Clin Microbiol Rev, 2004. 17(1): p. 1-13.
10. Elion, G.B., et al., Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci U S A, 1977. 74(12): p. 5716-20.
11. Schaeffer, H.J., et al., 9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature, 1978. 272(5654): p. 583-5.
12. Prusoff, W.H., Synthesis and biological activities of iododeoxyuridine, an analog of thymidine. Biochim Biophys Acta, 1959. 32(1): p. 295-6.
13. Furgiuele, F.P., et al., The effectiveness of 5-iodo-2-deoxyuridine in the treatment of herpes simplex keratitis. Trans Am Ophthalmol Soc, 1962. 60: p. 243-59.
14. Vere Hodge, R.A., et al., Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir]. Antimicrob Agents Chemother, 1989. 33(10): p. 1765-73.
15. Beutner, K.R., Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Antiviral Res, 1995. 28(4): p. 281-90.
16. Rosecan, L.R., et al., Antiviral therapy with ganciclovir for cytomegalovirus retinitis and bilateral exudative retinal detachments in an immunocompromised child. Ophthalmology, 1986. 93(11): p. 1401-7.
17. Brady, R.C. and D.I. Bernstein, Treatment of herpes simplex virus infections. Antiviral Res, 2004. 61(2): p. 73-81.
18. Bronson, J.J., et al., Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. J Med Chem, 1989. 32(7): p. 1457-63.
19. Helgstrand, E., et al., Trisodium phosphonoformate, a new antiviral compound. Science, 1978. 201(4358): p. 819-21.
20. Katz, D.H., et al., Antiviral activity of 1-docosanol, an inhibitor of lipid-enveloped viruses including herpes simplex. Proc Natl Acad Sci U S A, 1991. 88(23): p. 10825-9.
21. Sacks, S.L., et al., Clinical efficacy of topical docosanol 10% cream for herpes simplex labialis: A multicenter, randomized, placebo-controlled trial. J Am Acad Dermatol, 2001. 45(2): p. 222-30.
22. Ernst, M.E. and R.J. Franey, Acyclovir- and ganciclovir-induced neurotoxicity. Ann Pharmacother, 1998. 32(1): p. 111-3.
23. Johnson, G.L., et al., Acute renal failure and neurotoxicity following oral acyclovir. Ann Pharmacother, 1994. 28(4): p. 460-3.
24. Betz, U.A., et al., Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293. Antimicrob Agents Chemother, 2002. 46(6): p. 1766-72.
25. Crute, J.J., et al., Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nat Med, 2002. 8(4): p. 386-91.
26. Duan, J., et al., Oral bioavailability and in vivo efficacy of the helicase-primase inhibitor BILS 45 BS against acyclovir-resistant herpes simplex virus type 1. Antimicrob Agents Chemother, 2003. 47(6): p. 1798-804.
27. Kleymann, G., et al., New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat Med, 2002. 8(4): p. 392-8.
28. Danve-Szatanek, C., et al., Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. J Clin Microbiol, 2004. 42(1): p. 242-9.
29. Morfin, F. and D. Thouvenot, Herpes simplex virus resistance to antiviral drugs. J Clin Virol, 2003. 26(1): p. 29-37.
30. Gong, Y., et al., Preclinical evaluation of docusate as protective agent from herpes simplex viruses. Antiviral Res, 2001. 52(1): p. 25-32.
31. Cheng, H.Y., et al., Putranjivain A from Euphorbia jolkini inhibits both virus entry and late stage replication of herpes simplex virus type 2 in vitro. J Antimicrob Chemother, 2004. 53(4): p. 577-83.
32. Wachsman, M.B., et al., Enterocin CRL35 inhibits late stages of HSV-1 and HSV-2 replication in vitro. Antiviral Res, 2003. 58(1): p. 17-24.
33. Larkin, J., et al., Synergistic antiviral activity of human interferon combinations in the hepatitis C virus replicon system. J Interferon Cytokine Res, 2003. 23(5): p. 247-57.
34. Odds, F.C., Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother, 2003. 52(1): p. 1.
35. Kuo, Y.C., et al., Regulation of herpes simplex virus type 1 replication in Vero cells by Psychotria serpens: relationship to gene expression, DNA replication, and protein synthesis. Antiviral Res, 2001. 51(2): p. 95-109.
36. Greco, A., A.M. Laurent, and J.J. Madjar, Repression of beta-actin synthesis and persistence of ribosomal protein synthesis after infection of HeLa cells by herpes simplex virus type 1 infection are under translational control. Mol Gen Genet, 1997. 256(3): p. 320-7.
37. White, R.E., High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery. Annu Rev Pharmacol Toxicol, 2000. 40: p. 133-57.
38. Gadler, H., A. Larsson, and E. Solver, Nucleic acid hybridization, a method to determine effects of antiviral compounds on herpes simplex virus type 1 DNA synthesis. Antiviral Res, 1984. 4(1-2): p. 63-70.
39. Bronstein, J.C. and P.C. Weber, A colorimetric assay for high-throughput screening of inhibitors of herpes simplex virus type 1 alkaline nuclease. Anal Biochem, 2001. 293(2): p. 239-45.
40. Spector, F.C., et al., Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex. J Virol, 1998. 72(9): p. 6979-87.
41. Wentland, M.P., et al., Antiviral properties of 3-quinolinecarboxamides: a series of novel non-nucleoside antiherpetic agents. Drug Des Discov, 1997. 15(1): p. 25-38.
42. Rabalais, G.P., M.J. Levin, and F.E. Berkowitz, Rapid herpes simplex virus susceptibility testing using an enzyme-linked immunosorbent assay performed in situ on fixed virus-infected monolayers. Antimicrob Agents Chemother, 1987. 31(6): p. 946-8.
43. Rosenthal, K.S., C.M. Hodnichak, and J.L. Summers, Flow cytometric evaluation of anti-herpes drugs. Cytometry, 1987. 8(4): p. 392-5.
44. Prichard, M.N., et al., A microtiter virus yield reduction assay for the evaluation of antiviral compounds against human cytomegalovirus and herpes simplex virus. J Virol Methods, 1990. 28(1): p. 101-6.
45. Kodama, E., et al., Evaluation of antiherpetic compounds using a gastric cancer cell line: pronounced activity of BVDU against herpes simplex virus replication. Microbiol Immunol, 1996. 40(5): p. 359-63.
46. Yasin, B., et al., Evaluation of the inactivation of infectious Herpes simplex virus by host-defense peptides. Eur J Clin Microbiol Infect Dis, 2000. 19(3): p. 187-94.
47. Schmidtke, M., et al., A rapid assay for evaluation of antiviral activity against coxsackie virus B3, influenza virus A, and herpes simplex virus type 1. J Virol Methods, 2001. 95(1-2): p. 133-43.
48. Aguilar, J.S., et al., Dimethyl sulfoxide blocks herpes simplex virus-1 productive infection in vitro acting at different stages with positive cooperativity. Application of micro-array analysis. BMC Infect Dis, 2002. 2(1): p. 9.
49. Akanitapichat, P. and K.F. Bastow, The antiviral agent 5-chloro-1,3-dihydroxyacridone interferes with assembly and maturation of herpes simplex virus. Antiviral Res, 2002. 53(2): p. 113-26. | en |